MCM
FHTX icon

MAI Capital Management’s Foghorn Therapeutics FHTX Stock Holding History

MAI Capital Management’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$168 Buy
+35
New +$192 ﹤0.01% 4656

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

MAI Capital Management's FHTX Position: Q1 2026 in Review

MAI Capital Management opened a new position in Foghorn Therapeutics (FHTX) in Q1 2026: 35 shares worth $168. The stake represents ﹤0.01% of the portfolio and ranks #4656 among its holdings.

105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • MAI Capital Management held 35 shares of Foghorn Therapeutics worth $168 as of Q1 2026.
  • Foghorn Therapeutics was a new MAI Capital Management position in Q1 2026.
  • Foghorn Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4656 holding.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.